# US 2010/0221282 A1 · Recombinant vaccine against west nile virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0221282 A1
- Document ID: US20100221282A1
- Status: Published application
- Kind: A1
- Application number: 12/758,500
- Filed: 2010-04-12
- Published: 2010-09-02
- Earliest claimed: 2001-04-06
- Assignees: Merial Limited
- Inventors: SHEENA MAY LOOSMORE; JEAN-CHRISTOPHE FRANCIS AUDONNET; JULES MAARTEN MINKE
- Web page: https://patentgrep.com/patent/US20100221282A1

## CPC

- A61K 39/12: Viral antigens
- C07K 14/005: from viruses
- C12N 15/86: Viral vectors
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N 2710/00088: for redistribution
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24143: viral genome or elements thereof as genetic vector
- C12N 2799/023: where the vector is derived from a poxvirus
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An immunogenic or vaccine composition to induce an immune response or protective immune response against West Nile virus (WNV) in an animal susceptible to WNV. The composition includes a pharmaceutically or veterinarily acceptable vehicle or excipient, and a vector. The vector contains heterologous nucleic acid molecule(s), expresses in vivo in the animal WNV antigen, immunogen or epitope thereof, e.g., WNV E; WNV prM and E; WNV M and E; WNV prM, WNV M and E, WNV polyprotein prM-E, WNV polyprotein M-E, or WNV polyprotein prM-M-E. The composition can contain an adjuvant, such as carbomer. Methods for making and using such a composition, including prime-boost regimes and including as to differential diagnosis, are also contemplated.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A composition comprising a vector comprising a recombinant virus or DNA plasmid comprising a polynucleotide that encodes and expresses in vivo in an animal WNV (West Nile Virus) E, WNV M, WNV prM, WNV NS2A, WNV NS2B, WNV NS3, WNV polyprotein prM-E, WNV polyprotein M-E, WVN polyprotein prM-M, WNV polyprotein prM-M-E, or WNV polyprotein NS2A-NS2B-NS3.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the recombinant virus is a recombinant poxvirus.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the recombinant poxvirus is a canarypox or fowlpox virus.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the canarypox virus is ALVAC and the fowlpox virus is TROVAC.

### Claim 34 (depends on 30)

The composition of claim 30, wherein the polynucleotide comprises nucleotides having at least 95% sequence identity to nucleotides 466-741, 742-966, 967-2469, 466-2469, 466-966, 742-2469, 466-741 and 967-2469, 3526-4218, 4219-4611, 4612-6468, or 3526-6468 of SEQ ID NO:66 encoding WNV prM, M, E, prM-M-E, prM-M, M-E, prM-E, NS2A, NS2B, NS3, or NS2A-NS2B-NS3, respectively.

### Claim 35 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides 466-741 of SEQ ID NO:66 encoding WNV prM.

### Claim 36 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides 742-966 of SEQ ID NO:66 encoding WNV M.

### Claim 37 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides 967-2469 of SEQ ID NO:66 encoding WNV E.

### Claim 38 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides 466-2469 of SEQ ID NO:66 encoding WNV prM-M-E.

### Claim 39 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 466-966 of SEQ ID NO:66 encoding WVN prM-M.

### Claim 40 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 742-2469 of SEQ ID NO:66 encoding WVN M-E.

### Claim 41 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 466-741 and 967-2469 of SEQ ID NO:66 encoding WVN prM-E.

### Claim 42 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 3526-4218 of SEQ ID NO:66 encoding NS2A.

### Claim 43 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 4219-4611 of SEQ ID NO:66 encoding NS2B.

### Claim 44 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 4612-6468 of SEQ ID NO:66 encoding NS3.

### Claim 45 (depends on 34)

The composition of claim 34, wherein the nucleic acid molecule comprises nucleotides having at least 95% sequence identity to nucleotides of 3526-6468 of SEQ ID NO:66 encoding NS2A-NS2B-NS3.

### Claim 46 (depends on 30)

The composition of claim 30, wherein the polynucleotide encodes and expresses WVN prM-M-E having the amino acid sequence as set forth in SEQ ID NO:59.

### Claim 47 (depends on 30)

The composition of claim 30 further comprising an adjuvant.

### Claim 48 (depends on 47)

The composition of claim 47, wherein the adjuvant is a carbomer.

### Claim 49 (depends on 30)

The composition of claim 30 further comprising an antigen or immunogen or epitope thereof of a pathogen other than WNV of the animal, or a vector that contains and expresses in vivo in the animal a nucleic acid molecule encoding the antigen, immunogen or epitope thereof, or an inactivated or attenuated pathogen other than WNV of the animal.

### Claim 50 (depends on 30)

A method for inducing a protective immune response against WNV in an animal comprising administering to the animal the composition of claim 30.

### Claim 51 (depends on 50)

The method of claim 50 additionally comprising an adjuvant.

### Claim 52 (depends on 51)

The method of claim 51, wherein the adjuvant comprises a carbomer.

### Claim 53 (depends on 49)

A method for inducing a protective immune response against WNV and a second pathogen in an animal comprising administering to the animal the composition of claim 49.

### Claim 54 (depends on 30)

A method for inducing a protective immune response against WNV in an animal comprising administering to the animal (a) the composition of claim 30, and (b) an inactivated WNV vaccine, an attenuated WNV vaccine, or a subunit vaccine comprising WNV isolated antigen or immunogen, wherein (a) is administered prior to (b) in a prime-boost regimen, or (b) is administered prior to (a) in a prime-boost regimen, or (a) and (b) are administered together, either sequentially or in admixture.

### Claim 55 (depends on 50, 53, 54)

The method of claim 50, 53 or 54, wherein the animal is equine, avian, feline, or canine.
